Pre-Conference Workshop
Overview
Day 1
Day 2
Distinguished Faculty
Register
PDF Download
Hotel & Travel
Sponsor
Press Pass
Request Brochure

Complimentary Whitepaper

Partnering Best Practices for R&D Project Teams
William C. Ronco, Ph.D., President, Gathering Pace Consulting

Drug Development China


	Conference Proceeding CD Now Available Single Copy - $500.00Site License - $995.00	Speaker Presentations Poster Abstracts and More!

Register Today!

A New Way to Discover Innovative Medicine: Approach from the East Li Chen, Ph.D., Chief Scientiﬁc Ofﬁcer, Roche R&D Center (China) Ltd	Aligning Business, Corporate, and International Tax Strategy Rickey Pate, MBA, JD, Director of Global Tax, Eli Lilly and Company
How to Balance Internal and External Resources to Provide DMPK Support for Drug Discovery in China Ji Zhang, Ph.D., Director, DMPK, GlaxoSmithKline R&D China	Building an Integrated Biomedical Institute for Innovative Medicine in China Ling Chen, Ph.D., Director General, Guangzhou Institute of Biomedicine and Health, Chinese Academy of Sciences
Drug Discovery R&D in China: From Functional Capacity Outsourcing to Integrative Partnership Guoxin Zhu, Ph.D., Director, Discovery Chemistry Research & Technology, Eli Lilly & Company	Accelerate Oncology Clinical Development in Asia Michael Shi, Ph.D., Director and Biomarker Project Leader, Exploratory Oncology Development, Novartis
The Latest Insights from China into Translational Research for Cancer Jun Ren, M.D., Ph.D., Clinical Trials Coordination, Peking University School of Oncology/Beijing Cancer Hospital	Strategic Planning for Clinical Development Operations in China: Legal and Regulatory Considerations Shaoyu Chen, Senior Counsel, Development & Regulatory Law Group, Amgen Inc.

Three Days of Interactive Discussions, Case Studies, Break-out Roundtables, and Panels

In-Licensing, Out-Licensing, and Risk Sharing: The China Landscape for Partnership Deals
Interactions and Initiatives Taken for Drug Development Between China and the Rest of Asia: A Focus on Oncology
Opportunities for Drug Discovery in China: Chemistry, Biology, Integrated Projects, & Traditional Chinese Medicine
How to Conduct High Quality, Cost Effective GLP Safety Studies in China
Strategic Planning for Clinical Development Operations in China
Comparative Assessment of Regulatory Processes and Time Lines
The Role of Academic Clinical Trials Units for Drug Development in Asia
Business Model Case Studies: Real Challenges and Strategies to Harness R&D Capabilities in China

Pre-Conference Workshop - September 16, 2008

Improving China Drug Development Team Performance: Essential Partnering Strategies, Skills & Processes
Click here for full details on the pre-conference workshop.

On-Demand Webinar: The Impact of the Covance-WuXi Joint Venture
Click here to Listen to a pre-recorded webinar hosted by CHI's sister company, Cambridge Healthtech Associates (CHA), that was held on July 2, 2008.

During this complimentary, online session the following was discussed:

Why Covance and WuXi created this joint venture
How it may change pricing, services, and speed of growth in the pharma services sector in China
Implications on the competitive dynamics between providers (i.e. Bridge, WuXi, CRL-China,
Medicilon-MPI, government labs, etc).

For questions about this conference, contact:
Micah Lieberman
Conference Director, Pharmaceutical Strategy Series
Cambridge Healthtech Institute
Tel: +1 541.482.4709
E-mail: mlieberman@pharmaseries.com

For partnership and sponsorship opportunities, contact:
Arnold Wolfson
Manager, Business Development
Cambridge Healthtech Institute
Tel: +1 781.972.5431
E-mail: awolfson@healthtech.com